[go: up one dir, main page]

WO2016112078A3 - Anti-phf-tau antibodies and their uses - Google Patents

Anti-phf-tau antibodies and their uses Download PDF

Info

Publication number
WO2016112078A3
WO2016112078A3 PCT/US2016/012293 US2016012293W WO2016112078A3 WO 2016112078 A3 WO2016112078 A3 WO 2016112078A3 US 2016012293 W US2016012293 W US 2016012293W WO 2016112078 A3 WO2016112078 A3 WO 2016112078A3
Authority
WO
WIPO (PCT)
Prior art keywords
phf
tau
tau antibodies
isolated antibody
light chain
Prior art date
Application number
PCT/US2016/012293
Other languages
French (fr)
Other versions
WO2016112078A2 (en
Inventor
Jamie Fisher
Eilyn Lacy
Thomas Malia
Tadas Panavas
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of WO2016112078A2 publication Critical patent/WO2016112078A2/en
Publication of WO2016112078A3 publication Critical patent/WO2016112078A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to anti- PHF-tau antibodies and methods of making and using them. One embodiment of the invention is an isolated antibody that binds PHF-tau comprising an antigen-binding site of a heavy chain variable region (VH) of SEQ ID NOs: 20, 22 or 23. Another embodiment of the invention is an isolated antibody that binds PHF-tau comprising certain heavy and light chain complementarity determining regions or heavy chain and light chain variable regions.
PCT/US2016/012293 2015-01-08 2016-01-06 Anti-phf-tau antibodies and their uses WO2016112078A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101031P 2015-01-08 2015-01-08
US62/101,031 2015-01-08

Publications (2)

Publication Number Publication Date
WO2016112078A2 WO2016112078A2 (en) 2016-07-14
WO2016112078A3 true WO2016112078A3 (en) 2016-09-01

Family

ID=56356570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/012293 WO2016112078A2 (en) 2015-01-08 2016-01-06 Anti-phf-tau antibodies and their uses

Country Status (1)

Country Link
WO (1) WO2016112078A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894829B2 (en) 2017-02-27 2021-01-19 Teijin Pharma Limited Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
US11702467B2 (en) 2020-06-25 2023-07-18 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009817A (en) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof.
TWI853617B (en) 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 Anti-tau antibodies and uses thereof
EP3774888A4 (en) * 2018-03-05 2021-12-29 Janssen Pharmaceutica NV Anti-phf-tau antibodies and uses thereof
US20220017611A1 (en) * 2018-12-13 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
KR20220166308A (en) * 2020-04-08 2022-12-16 얀센 바이오테크 인코포레이티드 Anti-PHF-tau Antibodies and Uses Thereof
US20250134952A1 (en) 2021-09-20 2025-05-01 Institut National de la Santé et de la Recherche Médicale Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162336A1 (en) * 1991-12-06 2009-06-25 Max-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V. Novel Tools for the Diagnosis and Treatment of Alzheimer's Disease
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162336A1 (en) * 1991-12-06 2009-06-25 Max-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V. Novel Tools for the Diagnosis and Treatment of Alzheimer's Disease
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"MAPT/PHF-tau Antibody, Rabbit PAb (Cat # 10058-RP01", 8 June 2012 (2012-06-08), pages 1 - 2., Retrieved from the Internet <URL:www.sinobiologicalcdn.com/upload/MSDS/10058-RP01.pdf> [retrieved on 20160411] *
AUGUSTINACK ET AL.: "Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease", ACTA NEUROPATHOL., vol. 103, January 2002 (2002-01-01), pages 26 - 35, XP002625811, doi:10.1007/S004010100423 *
D'ABRAMO ET AL.: "Tau passive immunotherapy in mutant P301 L mice: antibody affinity versus specificity", PLOS ONE., vol. 8, no. e62402., 29 April 2013 (2013-04-29), pages 1 - 10 *
LICHTENBERG-KRAAG ET AL.: "Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau", PROC NATL ACAD SCI USA, vol. 89, 15 June 1992 (1992-06-15), pages 5384 - 5388, XP002226003, doi:10.1073/pnas.89.12.5384 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894829B2 (en) 2017-02-27 2021-01-19 Teijin Pharma Limited Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
US11739143B2 (en) 2017-02-27 2023-08-29 Teijin Pharma Limited Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
US11702467B2 (en) 2020-06-25 2023-07-18 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413

Also Published As

Publication number Publication date
WO2016112078A2 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
WO2016112078A3 (en) Anti-phf-tau antibodies and their uses
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
NZ626269A (en) Anti-phf-tau antibodies and their uses
EP3712178A4 (en) Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CR20170026A (en) HUMANIZED ANTI-TAU ANTIBODIES
UY37694A (en) HUMANIZED ANTIGEN UNION DOMAINS AND METHODS OF USE
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
EP4491195A3 (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
ES2687282T3 (en) ANTI-CD134 (OX40) humanized antibodies and their uses
MX388181B (en) ANTI-PD-1 ANTIBODIES.
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
NZ728749A (en) Anti-pd-l1 antibodies
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201990672A1 (en) ANTIBODIES SPECIFICALLY RELATING TO PD-1, AND THEIR FUNCTIONAL FRAGMENTS
MX2016008794A (en) E. coli specific antibody sequences.
HK1258204A1 (en) Antibodies targeting cd32b and methods of use thereof
MX366359B (en) Humanized antibodies against ceacam1.
HK1250649A1 (en) Anti-s100a8 for treating leukemia
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
AU2017255888A1 (en) Humanized anti-BASIGIN antibodies and the use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16735340

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16735340

Country of ref document: EP

Kind code of ref document: A2